方法：选取我院在2013-12/2015-12期间收治的、符合纳入标准的MHRD患者78例83眼。根据患者是否应用PPV联合ILMP治疗，随机分为试验组(39例40眼)和对照组(39例43眼)，对照组应用PPV治疗。观察两组治疗效果； 随访6mo后，比较两组患者视力改善情况以及手术前和手术后3、6mo的平均最佳矫正视力(best corrected visual acuity，BCVA)； 并记录术后并发症发生情况。

结果：治疗效果：与对照组相比，试验组的视网膜复位率为92%(37/40)，具有统计学差异(χ²=6.882，P=0.009)； 视力改善情况：试验组的视力改善情况较对照组好，差异有统计学意义(χ²=14.216，P<0.001)； 术后BCVA：试验组术后3、6mo的BCVA显著高于对照组，差异有统计学意义(t=7.119，P<0.001； t=10.573，P<0.001)； 并发症：与对照组相比，试验组发生眼内压增高和视野缺损的情况较少，具有统计学差异(χ²=11.323，P=0.001； χ²=8.573， P=0.003)； 晶状体混浊发生率无明显改变，但差异有统计学意义(χ²=1.835，P=0.176)。

结论：MHRD患者应用PPV联合ILMP术后恢复情况好，并发症发生率低，能更好地提高患者视网膜复位效果。

METHODS: Totally 78 patients with MHRD from December 2013 to December 2015 in our hospital were randomly divided into control group(39 patients 43 eyes)and experimental group(39 patients 40 eyes). The control group was treated with PPV, experimental group with PPV combined with ILMP. We observed the therapeutic effect and recorded the occurrence of postoperative complications. After 6mo follow-up, the vision improvement of the two groups were compared as the average of the best corrected visual acuity(BCVA)before and at 3, 6mo after surgery.

RESULTS: The reattachment rate of experimental group was 92%(37/40)with significant difference compared with control group(χ²=6.882, P=0.009). The improvement of visual acuity in the experimental group was better than that in the control group(χ²=14.216, P<0.001). The postoperative BCVA of the experimental group at 3 and 6mo was significantly higher than that of the control group(t=7.119, P<0.001; t=10.573, P<0.001). There were less patients with the situation of increased intraocular pressure and visual field defect(χ²=11.323, P=0.001; χ²=8.573, P=0.003). The lens opacity occurrence rate had not significantly changed(χ²=1.835, P=0.176).

CONCLUSION: MHRD patients treated with PPV combined with ILMP recovered better and the incidence of complications was lower. It can improve the patient's retinal restoration effect more.